

DAFTAR PUSTAKA

- Andersen, et al. (2016). *Factors affecting outcome in myasthenia gravis. Muscle & Nerve*, 54(6), 1041–1049. doi:10.1002/mus.25205
- Bauer, P. R., Ostermann, M., Russell, L., Robba, C., David, S., Ferreyro, B. L., Cid, J., Castro, P., Juffermans, N. P., Montini, L., Pirani, T., Van De Louw, A., Nielsen, N., Wendon, J., Brignier, A. C., Schetz, M., Kielstein, J. T., Winters, J. L., Azoulay, E., ... Burghi, G. 2022. Plasma exchange in the intensive care unit: a narrative review. *Intensive Care Medicine*, 48(10), 1382–1396.
- Beloor SA, Asuncion RMD. Myasthenia Gravis. [Updated 2022 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK559331/>
- Bento-Abreu, A., Velasco, A., Polo-Hernández, E., Pérez-Reyes, P.L., Tabernero, A. and Medina, J.M., 2008. Megalin is a receptor for albumin in astrocytes and is required for the synthesis of the neurotrophic factor oleic acid. *Journal of neurochemistry*, 106(3), pp.1149-1159.
- Bird SJ, Shefner JM, Goddeau RP. Clinical Manifestations of Myasthenia Gravis (Internet). Uptodate. 2022 (cited 15 Desember 2022). Available from <https://www.uptodate.com/contents/clinical-manifestations-of-myasthenia-gravis>
- Campanucci V, Krishnaswamy A & Cooper E (2008). *Mitochondrial reactive oxygen species inactivate neuronal nicotinic acetylcholine receptors and induce long-term depression of fast nicotinic synaptic transmission. J Neurosci* 28, 1733–1744
- Casulleras, M., Zhang, I. W., & Cristina, L. 2020. *Immunopathology in Acute-on-Chronic Liver Failure*. 1–18.
- Chang C-C, Yeh J-H, Chiu H-C, Liu T-C, Chen Y-M, Jhou M-J and Lu C-J (2023). Assessing the length of hospital stay for patients with myasthenia gravis based on the data mining MARS approach. *Front. Neurol.* 14:1283214.
- Chen, J., Tian, D. C., Zhang, C., Li, Z., Zhai, Y., Xiu, Y., Gu, H., Li, H., Wang, Y., & Shi, F. D. 2020. Incidence, mortality, and economic burden of myasthenia gravis in China: A nationwide population-based study. *The Lancet Regional Health - Western Pacific*, 5, 100063.
- Chien, C. Y., Chang, C. W., Liao, M. F., Chu, C. C., Ro, L. S., Wu, Y. R., Chang, K. H., Chen, C. M., & Kuo, H. C. 2023. Myasthenia gravis and independent risk factors for recurrent infection: a retrospective cohort study. *BMC Neurology*, 23(1), 1–11. <https://doi.org/10.1186/s12883-023-03306-3>
- China, L., Maini, A., Skene, S. S., Shabir, Z., Sylvestre, Y., Colas, R. A., et al. (2018). *Albumin Counteracts Immune-Suppressive Effects of Lipid Mediators in Patients With Advanced Liver Disease. Clinical Gastroenterology and Hepatology*, 16(5), 738–747.e7.
- Diez P. L., Homedes, C., Alberti, M.A., Velez Santamaria, V. Quality of Life in Myasthenia Gravis and Correlation of MG-QOL15 with Other Functional Scales. *J. Clin. Med.* 2022, 11, 2189.

- Díez-Porras L, Homedes C, Alberti MA, Vélez-Santamaría V, Casasnovas C. *Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis*. Sci Rep. 2020 Aug 11;10(1):13497.
- Dogra, A., Rana, K., Rathod, C., Prakash, S. *Outcome of therapeutic plasma exchange in Myasthenia gravis patients*. J Family Med Prim Care. 2020;9:5971-5.
- Drachman DB dan Amato AA. 2006. *Myasthenia Gravis and other Disease of the Neuromuscular Junction*. In : Hauser SL.ed. *Harrison's Neurology in Clinical Medicine*. San Fransisco: McGraw- Hill. Hal. 527-535.
- Dresser, L., Wlodarski, R., Rezanian, K., Soliven, B. *Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations*. J. Clin. Med. 2021, 10, 2235.
- El Soury, M., Fornasari, B.E., Carta, G., Zen, F., Haastert-Talini, K. and Ronchi, G., 2021. The role of dietary nutrients in peripheral nerve regeneration. *International Journal of Molecular Sciences*, 22(14):7417.
- Farmakidis, C., Pasnoor, M., Dimachkie, M. M., & Barohn, R. J. 2018. Treatment of Myasthenia Gravis. *Neurologic Clinics*, 36(2), 311–337.
- Farrugia, M. E., Carmichael, C., Cupka, B. J., Warder, J., Brennan, K. M., & Burns, T. M. (2014). *The modified rankin scale to assess disability in myasthenia gravis: Comparing with other tools*. *Muscle & Nerve*, 50(4), 501–507.
- Gilhus, N. E. 2016. Myasthenia Gravis. *New Englaf Journal of Medicine*, 375, 2570–2581.
- Hakim M, Susanti L, Arimbawa IK, Kurniani N. 2018. *Pedoman Tatalaksana GBS, CIDP, MG dan Imunoterapi*. Edisi I. PERDOSSI.
- Hansen, M., Neilson, L., Parikh, M., & Katirji, B. 2023. Greater Number of Plasma Exchanges Does Not Improve Outcome in Myasthenic Crisis. *Journal of Clinical Neuromuscular Disease*, 24(4), 199–206.
- Hernandez Fustes, O. J., Arteaga Rodriguez, C., & Hernandez Fustes, O. J. 2020. Myasthenia Gravis with Elderly Onset at Advanced Age. *Cureus*, 12(1), 1–5.
- Huang, Y., Tan, Y., Shi, J., Li, K., Yan, J., & Guan, Y. 2021. Patients With Myasthenia Gravis With Acute Onset of Dyspnea: Predictors of Progression to Myasthenic Crisis and Prognosis. *Frontiers in Neurology*, 12(November), 1–9.
- Ipe, T.S., Davis, A.R., Raval, J.S. 2021. Therapeutic Plasma Exchange in Myasthenia Gravis: A Systematic Literature Review and Meta-Analysis of Comparative Evidence. *Front. Neurol.* 12:662856.
- Kemenkes RI. 2010. Riset Kesehatan Dasar, RISKESDAS. Jakarta: Balitbang Kemenkes RI
- Kothari MJ. 2004. Myasthenia Gravis. *JAOA*. 104(9): 377-384.
- Krishnaswamy A, Cooper E. *Reactive oxygen species inactivate neuronal nicotinic acetylcholine receptors through a highly conserved cysteine near the intracellular mouth of the channel: implications for diseases that involve oxidative stress*. J Physiol. 2012;590:39-47.
- Kumar, R., Paul, S.B., Gupta, S., Singh, G., Kaur, A. Therapeutic plasma exchange in the treatment of myasthenia gravis. *Indian J Crit Care Med*. 2015;19:9-13.
- LeVine, S. M. 2016. Albumin and multiple sclerosis. *BMC Neurology*, 16(1).
- Mandawat, A., Kaminski, H. J., Cutter, G., Katirji, B., & Alshekhlee, A. 2010.

- Comparative analysis of therapeutic options used for myasthenia gravis. *Annals of Neurology*, 68(6), 797–805.
- McLeod, B.C., 2012. Plasma and plasma derivatives in therapeutic plasmapheresis. *Transfusion*, 52:38S-44S.
- Melzer, N., Ruck, T., Fuhr, P., Gold, R., Hohlfeld, R., Marx, A., *et al.* 2016. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. *Journal of Neurology*, 263(8), 1473–1494.
- Mouri MI, Badireddy M. Hyperglycemia. [Updated 2023 Apr 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK430900/>
- Nehring J, Schirmbeck LA, Friebus-Kardash J, Dubler D, Huynh-Do U, Chizzolini C, Ribi C and Trendelenburg M. 2018. *Autoantibodies Against Albumin in Patients With Systemic Lupus Erythematosus*. *Front. Immunol.* 9:2090. doi: 10.3389/fimmu.2018.02090
- Nelke C, Stascheit F, Eckert C, Pawlitzki M, Schroeter CB, Huntemann N *et al.* Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients. *J Neuroinflammation*. 2022 Apr 12;19(1):89.
- Nicolle MW. 2002. Myasthenia Gravis. *The neurologist*. 8(1): 2-21.
- Paiva G, Kouyoumdjian J. 2022. Comparison of clinical and electrophysiological characteristics in Myasthenia Gravis patients with favorable and unfavorable outcomes. *Neurology.org*
- Pasqualin, F., Guidoni, S. V., Ermani, M., Pegoraro, E., & Bonifati, D. M. 2020. Outcome measures and treatment effectiveness in late onset myasthenia gravis. *Neurological Research and Practice*, 2(1).
- Prajapati, K. D., Sharma, S. S., Roy, N. 2011. Current perspectives on potential role of albumin in neuroprotection. *Reviews in the Neurosciences*, 22(3).
- Pinzon R. 2009. Myasthenia Gravis. *Cermin Dunia Kedokteran*. 172(36): 413-416.
- Rajesh *et al.* 2015. *Therapeutic plasma exchange in the treatment of myasthenia gravis*. *Indian Journal of Critical Care Medicine*, 19(1), 9.
- Ramsaroop, T., Gelinas, D., Kang, S. A., & Govindarajan, R. 2023. Analysis of length of stay and treatment emergent complications in hospitalized myasthenia gravis patients with exacerbation. *BMC Neurology*, 23(1), 1–11.
- Romi, F., Gilhus, N. E., Aarli, J. A. 2005. Myasthenia gravis: clinical, immunological, and therapeutic advances. *Acta Neurologica Scandinavica*, 111(2), 134–141.
- Sanders, D.B., Wolfe, G.I., Benatar, M., Evoli, A., Gilhus, N.E., Illa, I.; Kuntz, N *et al.* International consensus guidance for management of myasthenia gravis: Executive summary. *Neurology* 2016, 87, 419–425
- Schneider-Gold, C., Gajdos, P., Toyka, K. V., & Hohlfeld, R. R. 2005. Corticosteroids for myasthenia gravis. *Cochrane Database of Systematic Reviews*, 2011(6).
- Sharma S, Lal V, Prabhakar S, Agarwal R. Clinical profile and outcome of myasthenic crisis in a tertiary care hospital: A prospective study. *Ann Indian Acad Neurol*. 2013 Apr;16(2):203-7.

- Silvestri, N. J., Wolfe, G. I. 2018. *Myasthenia Gravis: Classification and Outcome Measurements. Myasthenia Gravis and Related Disorders*, 307–318.
- Soeters, P. B., Wolfe, R. R., Shenkin, A. 2018. *Hypoalbuminemia: Pathogenesis and Clinical Significance. Journal of Parenteral and Enteral Nutrition*.
- Sosinsky, M.S., Kaufmann, P. 2007. *Myasthenia Gravis & Other Disorders of the Neuromuscular Junction. in: Brust JCM (ed.). Neurology: Current Diagnosis and Treatment*. USA: Lange Medical Books/McGraw-Hill. Hal. 350-356
- Suresh, A. B., & Ria Monica D. Asuncion. 2023. Myasthenia gravis. In *NCBI Bookshelf*. StatPearls Publishing.
- Tabernero, A., Granda, B., Medina, A., Sánchez-Abarca, L.I., Lavado, E. and Medina, J.M., 2002. Albumin promotes neuronal survival by increasing the synthesis and release of glutamate. *Journal of neurochemistry*, 81(4): 881-891.
- Tiamkao, S., Pranboon, S., Thepsuthammarat, K., & Sawanyawisuth, K. 2014. Prevalence of factors associated with poor outcomes of hospitalized myasthenia gravis patients in Thailand. *Neurosciences*, 19(4), 286–290.
- Thomsen, J.L.S., Andersen, H. 2020. Outcome Measures in Clinical Trials of Patients With Myasthenia Gravis. *Front. Neurol.* 11:596382.
- Tunc, A. 2019. Early predictors of functional disability in Guillain-Barre Syndrome. *Acta Neurologica Belgica*. 119(4):555-559.
- Unger, J. K., Janssen, V. R., Kashefi, A., Haltern, C., Klosterhalfen, B., Fischer, Y., Gressner, A. M., & Rossaint, R. 2001. Enhancing filtration rates by the use of blood flow around the capillaries of plasmafilters: An in vitro study. *International Journal of Artificial Organs*, 24(11), 821–831.
- Utsugisawa, K., Suzuki, S., Nagane, Y., Masuda, M., Murai, H., Imai, T. 2014. *Health-related quality-of-life and treatment targets in myasthenia gravis. Muscle & Nerve*, 50(4), 493–500.
- Venkatesham. A, Sharath. P, Vidya. J, Krishna D. Effect of reactive oxygen species on cholinergic receptor function. *J India Pharmacol*. 2005;6:366–370
- Vernino S. Autoantibody Profiles and Neurological Correlations of Thymoma. *Clinical Cancer Research*. 2004;10(21):7270– 5.
- Wang, L., Zhang, Y., & He, M. 2017. Clinical predictors for the prognosis of myasthenia gravis. *BMC Neurology*, 17(1), 1–6.
- Ward ES, Gelinas D, Dreesen E, Van Santbergen J, Andersen JT, Silvestri NJ, Kiss JE, Sleep D, Rader DJ, Kastelein JJP, Louagie E, Vidarsson G and Spriet I. 2022. Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune Disorders. *Front. Immunol.* 13:892534.
- Wardoyo, S. 2022. Prognostic Factors of Myasthenia Gravis Remission After Thymectomy at National Referral Hospital in Indonesia. *The New Ropanasuri Journal of Surgery*, 7(2), 10–13.]
- Weng, Y.Y., Yang, D.H., Qian, M.Z., Wei, M.M., Yin, F., *et al.* 2016. Low serum albumin concentrations are associated with disease severity in patients with myasthenia gravis. *Medicine*, 95(39), e5000.
- Wiedermann, C. J. 2021. Hypoalbuminemia as surrogate and culprit of infections. *International Journal of Molecular Sciences*, 22(9).
- Wilcke, H., Glaubitz, S., Kück, F., Anten, C., Liebetanz, D., Schmidt, J., &

- Zschüntzsch, J. 2023. Female sex and overweight are associated with a lower quality of life in patients with myasthenia gravis: a single center cohort study. *BMC Neurology*, 23(1), 1–9.
- Wilde, B., & Katsounas, A. (2019). Immune Dysfunction and Albumin-Related Immunity in Liver Cirrhosis. *Mediators of Inflammation*, 2019, 1–9.
- Yang DH, Qian MZ, Wei MM, Li J, Yu MM, Lu XM, Yang H, Lin H, Li X, Zhu JY, Zhang X. The correlation of neutrophil-to-lymphocyte ratio with the presence and activity of myasthenia gravis. *Oncotarget*. 2017 Jun 16;8(44):76099-76107.
- Yang, D., Su, Z., Wu, S., Bi, Y., Li, X., Li, J., *et al.* 2016. Low antioxidant status of serum bilirubin, uric acid, albumin and creatinine in patients with myasthenia gravis. *International Journal of Neuroscience*, 126(12), 1120–1126.
- Yoshimoto Y, Ishida S, Hosokawa T, Arawaka S. Assessment of clinical factors affecting outcome of myasthenia gravis. *Muscle & Nerve*. 2021;1–5.
- Zhang, J., & H, W. 1998. Effectiveness of steroid treatment in juvenile myasthenia gravis. *Chinese Journal of Pediatrics*, 36(10), 612–614.
- Zhang, P., Yang, C. L., Du, T., Liu, Y. D., Ge, M. R., Li, H., Liu, R. T., Wang, C. C., Dou, Y. C., & Duan, R. S. 2021. Diabetes mellitus exacerbates experimental autoimmune myasthenia gravis via modulating both adaptive and innate immunity. *Journal of Neuroinflammation*, 18(1), 1–14.